Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium
Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA (S.M.C., K.R.L., M.D.P.); Pharmacotherapy Education and Research Center, University of Texas Health Science Center San Antonio, San Antonio, TX (J.G.K.); Department of Neuro-Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX (W.K.A.Y., M.R.G.); Dana-Farber Cancer Institute, Boston, MA (P.Y.W.); Neuro-Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD (H.A.F.); University of Wisconsin Hospital, Madison, WI (M.P.M., H.I.R.); Memorial Sloan-Kettering Cancer Center, New York, NY (L.M.D., L.E.A.); University of Pittsburgh Medical Center Cancer Pavilion, Division of Neuro-Oncology, Pittsburgh, PA (F.S.L.); Neuro-Oncology Program, David Geffen School of Medicine at UCLA, and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA (T.F.C.); USA
Address correspondence to Susan M. Chang, Department of Neurological Surgery, University of California San Francisco, 400 Parnassus Ave., A-808, San Francisco, CA 94143-0350, USA (changs{at}neurosurg.ucsf.edu).
 |
Abstract |
|---|
The North American Brain Tumor Consortium (NABTC) is a multi-institutional consortium with the primary objective of evaluating novel therapeutic strategies through early phase clinical trials. The NABTC has made substantial changes to the design and methodology of its trials since its inception in 1994. These changes reflect developments in technology, new types of therapies, and advances in our understanding of tumor biology and biological markers. We identify the challenges of early clinical assessment of therapeutic agents by reviewing the clinical trial effort of the NABTC and the evolution of the protocol template used to design trials. To better prioritize effort and allocation of patient resources and funding, we propose an integrated clinical trial design for the early assessment of efficacy of targeted therapies in neurooncology. This design would mandate tissue acquisition prior to therapeutic intervention with the drug, allowing prospective evaluation of its effects. It would also include a combined phase 0/I pharmacokinetic study to determine the safety and biologically optimal dose of the agent and to verify successful modulation of the target prior to initiating a larger, phase II efficacy study.
Keywords: brain tumor, clinical trials, North American Brain Tumor Consortium, targeted therapies
Received November 19, 2007; Accepted January 4, 2008
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. C. De Witt Hamer Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies Neuro Oncology, February 9, 2010; (2010) nop068v1. [Abstract] [Full Text] [PDF]
|
|